A child dies in an experimental gene-editing trial, prompting industry-wide questions

A six-year-old girl in China, identified by the pseudonym "Mei," tragically died in March 2025 following an experimental brain-targeted gene-editing therapy administered at Shanghai's Xinhua Hospital. The highly experimental treatment aimed to correct a genetic mutation causing a neurodevelopmental disorder. Her death was not publicly disclosed by the researchers or the institution for over a year, only coming to light through a joint investigation by *Science* and *Retraction Watch* in July 2026.

The incident has ignited significant industry-wide concerns regarding safety and ethical practices in gene-editing trials. Reports indicate that preclinical animal studies showed troubling liver and kidney damage, which experts suggest should have prompted further investigation before human trials. Furthermore, a *Nature* paper published by the research team in February 2026, detailing related preclinical findings, omitted any mention of Mei's treatment, her death, or the adverse animal study results, drawing sharp criticism for a lack of transparency. The hospital's ethics board concluded Mei's death was "definitely related" to the treatment.

This case has intensified global discussions on the oversight of personalized gene therapies and the necessity for robust ethical governance, transparency, and timely reporting of serious adverse events. Experts are questioning the appropriateness of testing highly experimental gene-editing therapies on non-life-threatening conditions and emphasizing the need for stricter regulations and enhanced patient protection in this rapidly evolving field. Shanghai Jiaotong University, affiliated with Xinhua Hospital, has since launched a comprehensive investigation into the clinical trial and related scientific publication.